⚕️ Medical Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any new health practice, especially if you have existing medical conditions or take medications.
Table of Contents
Pre-Screening Assessment
Before beginning a microdosing practice, it's essential to honestly evaluate your health status. Many conditions that are safe for everyday activities may present specific concerns with psilocybin use.
Self-Screening Questions
Consider these questions honestly before proceeding:
Are you taking any psychiatric medications, especially antidepressants, antipsychotics, or mood stabilizers?
Do you or close family members have a history of schizophrenia, bipolar disorder, or psychotic episodes?
Do you have any diagnosed heart conditions, valve problems, or take cardiac medications?
Do you have any chronic health conditions that require regular medication or monitoring?
Are you pregnant, planning to become pregnant, or currently breastfeeding?
Have you ever had a seizure or been diagnosed with epilepsy?
✅ Pre-Microdosing Checklist
- I have no personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder)
- I am not currently taking MAOIs, lithium, or tramadol
- I am not pregnant or breastfeeding
- I do not have severe heart valve disease
- I am in a stable mental state and not in acute crisis
- I have reviewed my current medications for interactions
- I understand this is my personal decision and responsibility
Contraindicated Conditions
Some conditions represent absolute or relative contraindications to psilocybin use. Understanding these is crucial for safety.
Absolute Contraindications
Conditions where psilocybin use should be avoided entirely
Schizophrenia Contraindicated
Psilocybin can trigger or worsen psychotic episodes in individuals with schizophrenia or schizoaffective disorder. This applies to both active conditions and those in remission.
Risk: Psychotic decompensation, hospitalization
Active Psychosis Contraindicated
Anyone currently experiencing psychotic symptoms (hallucinations, delusions, disorganized thinking) should not use psilocybin.
Risk: Symptom worsening, dangerous behavior
Lithium Use Contraindicated
Combining lithium with psilocybin has been associated with severe adverse reactions including seizures, cardiac events, and prolonged psychotic states.
Risk: Seizures, cardiac events, severe reactions
MAOI Medications Contraindicated
Monoamine oxidase inhibitors can cause dangerous interactions with psilocybin, potentially leading to serotonin syndrome.
Risk: Serotonin syndrome, hypertensive crisis
Relative Contraindications
Conditions requiring careful consideration and possibly medical guidance
Bipolar Disorder High Risk
Psilocybin may trigger manic or hypomanic episodes in individuals with bipolar disorder. Some clinical trials have cautiously included bipolar II patients, but risk remains.
Recommendation: Only consider under psychiatric supervision
Family History of Psychosis High Risk
First-degree relatives with schizophrenia, bipolar disorder with psychotic features, or other psychotic disorders indicate elevated genetic risk.
Recommendation: Carefully weigh risks; consider avoiding
Severe Depression with Suicidality High Risk
While psilocybin shows promise for depression, active suicidal ideation requires professional treatment first. Self-treatment is not appropriate.
Recommendation: Seek professional help; only use in clinical settings
Pregnancy/Breastfeeding High Risk
No safety data exists for psilocybin use during pregnancy or breastfeeding. Potential effects on fetal/infant development are unknown.
Recommendation: Avoid entirely during pregnancy and nursing
Cardiovascular Considerations
Heart and Vascular Health
Psilocybin's effects on the cardiovascular system require consideration
Cardiovascular Effects of Psilocybin
- Mild blood pressure increase: Typically 10-20 mmHg during acute effects
- Mild heart rate increase: Usually 5-15 BPM
- 5-HT2B receptor activation: Theoretical concern for valve effects with chronic use
Heart Valve Disease High Risk
Chronic 5-HT2B agonist exposure (like fenfluramine) has caused valvular heart disease. While microdose frequency is much lower, caution is warranted.
Recommendation: Discuss with cardiologist; consider echocardiogram monitoring if proceeding
Uncontrolled Hypertension Moderate Risk
Transient BP increases during dosing may be concerning if hypertension is not well-controlled.
Recommendation: Get BP controlled first; monitor during use
History of Heart Attack/Stroke Moderate Risk
Cardiovascular stress from even mild sympathomimetic effects may be concerning.
Recommendation: Consult cardiologist; microdoses likely lower risk than macrodoses
Arrhythmias Caution
Mild heart rate changes are typical. Significant arrhythmias warrant discussion with cardiologist.
Recommendation: Discuss with your cardiologist
Psychiatric Conditions
Mental Health Considerations
Mental health conditions require careful evaluation
| Condition | Risk Level | Considerations | Recommendation |
|---|---|---|---|
| Schizophrenia / Schizoaffective | Contraindicated | Risk of psychotic exacerbation; even microdoses may be destabilizing | Do not use |
| Bipolar I Disorder | High Risk | May trigger manic episodes; mood destabilization risk | Avoid or only under psychiatric supervision |
| Bipolar II Disorder | Moderate Risk | Lower but still present mania risk; some clinical trials have included | Caution; psychiatric guidance recommended |
| Major Depression (stable) | Caution | May be beneficial; some evidence for improvement | May proceed with awareness; don't replace proven treatments |
| Anxiety Disorders | Caution | May help or may initially increase anxiety | Start very low; monitor carefully |
| PTSD | Caution | Clinical trials showing promise; may bring up difficult material | Consider therapeutic context |
| OCD | Low Risk | Some evidence for benefit; serotonergic mechanism | May be helpful; monitor symptoms |
| ADHD | Low Risk | Anecdotal reports of focus improvement | May proceed; check stimulant interactions |
| Personality Disorders | Moderate Risk | Limited data; emotional volatility may be concern | Consider therapeutic support |
Neurological Conditions
Neurological Health
Conditions affecting the nervous system
Epilepsy / Seizure Disorders High Risk
Limited data on seizure threshold effects. Some reports suggest psilocybin may not increase risk, but caution warranted.
Recommendation: Consult neurologist; ensure seizure disorder is well-controlled
Cluster Headaches Low Risk
Interestingly, psilocybin shows promise for cluster headache prevention. Many cluster headache patients report benefit.
Recommendation: May be beneficial; research supports use
Migraines Low Risk
Some evidence for migraine reduction. Generally considered safe in migraine population.
Recommendation: May proceed; some may find benefit
Multiple Sclerosis Caution
Limited data. No known contraindication, but also no safety data specific to MS.
Recommendation: Discuss with neurologist; proceed cautiously if at all
Parkinson's Disease Caution
No specific contraindication, but consider interactions with Parkinson's medications.
Recommendation: Consult neurologist; check medication interactions
Traumatic Brain Injury (TBI) Moderate Risk
Altered brain function may affect psilocybin response unpredictably. Increased emotional lability may be concern.
Recommendation: Proceed with caution; start with very low doses
Medication Interactions
Drug Interactions
Understanding how psilocybin interacts with common medications
| Medication Class | Examples | Interaction | Recommendation |
|---|---|---|---|
| MAOIs | Phenelzine, tranylcypromine | Contraindicated Serotonin syndrome risk | Do not combine; 2+ week washout |
| Lithium | Lithium carbonate | Contraindicated Seizures, severe reactions | Do not combine |
| SSRIs | Sertraline, fluoxetine, escitalopram | Moderate Reduced effects; some SS risk | May reduce microdosing benefits; discuss tapering with doctor |
| SNRIs | Venlafaxine, duloxetine | Moderate Reduced effects; SS risk | Similar to SSRIs; medical guidance for tapering |
| Antipsychotics | Risperidone, olanzapine, quetiapine | Moderate Block psilocybin effects | Effects will be significantly reduced or absent |
| Benzodiazepines | Alprazolam, lorazepam | Low May reduce intensity | Can be used for anxiety management; may dampen effects |
| Stimulants | Adderall, Ritalin | Caution Increased cardiovascular effects | Consider skipping stimulant on dose days |
| Blood Pressure Meds | Various | Low Generally no significant interaction | Continue as prescribed; monitor BP |
| Thyroid Medications | Levothyroxine | Low No known interaction | Continue as prescribed |
| Diabetes Medications | Metformin, insulin | Low No known interaction | Continue as prescribed; monitor blood sugar |
For detailed interaction information, see our Interaction Severity Ratings guide.
Age-Specific Considerations
Young Adults
Key Concern: Brain development continues until ~25. Effects on developing brain are unknown.
Recommendation: Consider waiting until mid-20s; if proceeding, use minimal doses and frequency.
Adults
Key Concern: Generally appropriate age range. Consider individual health factors.
Recommendation: Standard precautions apply. Screen for conditions and medications.
Seniors
Key Concern: More likely to have conditions and medications. May be more sensitive to effects.
Recommendation: Start with lower doses; careful medication review; consider cardiac screening.
Ongoing Health Monitoring
If you choose to microdose, ongoing self-monitoring and periodic professional check-ins are prudent.
Before Starting
- Complete health screening questionnaire
- Review all current medications
- Consider baseline labs if indicated
- Document baseline mood/energy/focus
First 2 Weeks
- Daily journaling of effects
- Monitor for anxiety increase
- Track sleep quality
- Note any physical symptoms
Monthly Check-in
- Review journal for patterns
- Assess if goals are being met
- Note any concerning symptoms
- Consider dose adjustment
Every 3-6 Months
- Consider a break/washout period
- Reassess whether to continue
- If cardiac concerns: echocardiogram
- General health check-up
Annually
- Comprehensive health review
- Cardiac screening if long-term use
- Evaluate continued benefit
- Update medication review
Talking to Your Doctor
While discussing psilocybin use with healthcare providers can feel daunting, it's often important for comprehensive care.
🗣️ How to Approach the Conversation
Many people worry about judgment or legal consequences. Here are some approaches:
Option 1: Direct disclosure
"I've been researching psilocybin microdosing and I'm considering trying it. I want to make sure it's safe with my current medications and health conditions. Can we discuss this?"
Option 2: Hypothetical framing
"I've been reading about psychedelic research. If someone with my health profile were considering this, what would the concerns be?"
Option 3: Focus on interactions
"I want to review my medications for any potential interactions with serotonergic substances, including certain supplements and plant medicines."
What to Discuss
- Current medications: Get professional input on interactions
- Health conditions: Especially cardiac and psychiatric
- Family history: Particularly psychiatric conditions
- Baseline testing: What labs or tests might be prudent
- Monitoring plan: What to watch for and when to seek help
When to Seek Medical Help
🚨 Seek Immediate Medical Attention If:
When to Stop Microdosing and Seek Guidance
- New or worsening anxiety that persists on off-days
- Mood instability or emotional volatility
- Sleep disturbances that don't resolve
- Physical symptoms like persistent headaches or heart palpitations
- Worsening of any pre-existing condition
- Any concerning change in mental state
Key Medical Takeaways
- Absolute contraindications: Schizophrenia, active psychosis, lithium use, MAOIs
- High-risk conditions: Bipolar disorder, family history of psychosis, severe heart valve disease
- Medication review is essential: Many psychiatric medications interact
- SSRIs reduce effects: May need to taper (with medical guidance) for full benefit
- Age matters: Under 25 and over 65 require extra consideration
- Monitoring is wise: Track your response and get periodic check-ups
- Consider talking to a doctor: Especially if you have health conditions